News

Media Release

Hyphens Pharma’s Ceradan® range of products to enter major
Middle East markets

  • Marks Hyphens Pharma’s major expansion into the Middle East and the first time into Saudi Arabia, United Arab Emirates, Kuwait, Qatar and Bahrain for its Ceradan® proprietary product range

Download as PDF

Singapore, 29 February 2024 – Hyphens Pharma International Limited (“Hyphens Pharma”, “凯帆药剂国际有限公司”, or the “Company”, and together with its subsidiaries, the “Group”), Singapore’s leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that it has signed an exclusive distribution agreement with Cooper Pharma, S.A. (“Cooper Pharma”) for the Group’s Ceradan® range of products to be distributed in five Middle East countries, namely Saudi Arabia, United Arab Emirates, Kuwait, Qatar and Bahrain. Cooper Pharma will be responsible for the product registration and commercialisation of Ceradan® products in the five countries.

Founded in 1933, Cooper Pharma is the leading Moroccan pharmaceutical company with presence in Europe, Africa and the Middle East. Alongside its own brand, Cooper Pharma manufactures, imports, markets and promotes drugs under license from more than 20 international companies in various therapeutic areas. In the area of dermatology, Cooper Pharma promotes a range of prescription products, including antifungals to dermatologists.

Mr Lim See Wah (林世华), Executive Chairman and CEO of Hyphens Pharma commented: “Our proprietary Ceradan® range of products are now poised to expand into the major Middle East markets with the help of our partner, Cooper Pharma. Our focus on science-based research in the formulation of our Ceradan® products is bearing fruit, as it allows for not only better efficacy but advocacy as we continue to expand into markets in Asia and beyond. We hope that our Ceradan products can provide relief to sufferers of atopic dermatitis or eczema in the Middle East.”

Based on a recent multinational study investigating the 12-month prevalence of diagnosed atopic dermatitis in paediatric populations, the overall prevalence in Saudi Arabia was 19.8% while in the United Arab Emirates, it was 16.7%.1 Atopic dermatitis, often referred to as eczema, is a chronic (long-lasting) disease that causes dryness, inflammation, redness, and irritation of the skin. It is a common condition that usually begins in childhood; however, anyone can get the disease at any age.

Ceradan® is Hyphens Pharma’s flagship brand of dermatological products and it has a unique ceramide-dominant emollient formulation. Ceradan® products, which are scientifically-formulated and clinically-tested to relieve and tackle eczema-prone skin conditions, are poised to benefit from the growing eczema market in the Middle East.

Mr Ayman Cheikh Lahlou, CEO of Cooper Pharma said: “We are pleased to represent and market Hyphens Pharma’s Ceradan® range of products in the Middle East as we believe it will be a very welcome emollient therapy for dermatologists in the Middle East in the management of atopic dermatitis, especially in children.”

1 Silverberg JI, Barbarot S, Gadkari A, Simpson EL, Weidinger S, Mina-Osorio P, Rossi AB, Brignoli L, Saba G, Guillemin I, Fenton
MC, Auziere S, Eckert L. Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. Ann
Allergy Asthma Immunol. 2021 Apr;126(4):417-428.e2. doi: 0.1016/j.anai.2020.12.020. Epub 2021 Jan 6. PMID: 33421555

 

End.

 

About Hyphens Pharma International Limited (www.hyphensgroup.com)
Hyphens Pharma International Limited and its subsidiaries (the “Group“) is Singapore’s leading specialty pharmaceutical and consumer healthcare group, leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in Singapore, Vietnam, Malaysia, Indonesia and the Philippines, and is supplemented by a marketing and distribution network covering 10 other markets – Bangladesh, Brunei, Cambodia, China, Hong Kong S.A.R., Macau S.A.R., Myanmar, South Korea, Sri Lanka and Gulf Cooperation Council countries, including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and United Arab Emirates.

Singapore is the Group’s regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based. The Group’s core business comprises the following segments: Specialty Pharma Principals, Proprietary Brands, and Medical Hypermart & Digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies and an online pharmacy for doctors to prescribe and have medications delivered to their patients’ homes.

Issued on behalf of : Hyphens Pharma International Limited
For media enquires contact : Mr Derek Chng / Mr Gerald Woon
Email / DID / Mobile : [email protected] / (65) 6704 9285 / (65) 9638 8635
[email protected] / (65) 6704 9268 / (65) 9694 8364

This media release has been reviewed by the Company’s sponsor, SAC Capital Private Limited (the “Sponsor”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this media release, including the correctness of any of the statements or opinions made or reports contained in this media release.

The contact person for the Sponsor is Ms Lee Khai Yinn (Tel: (65) 6232 3210) at 1 Robinson Road, #21- 00 AIA Tower, Singapore 048542.